どうする?　超高齢患者・低リスク患者の抗凝固療法

出版社： メディカルサイエンス社
著者：
発行日： 2016-03-25
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784903843841
電子書籍版： 2016-03-25 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,750 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

2,200 円(税込)

購入する

商品紹介

新しい抗凝固薬の開発や知識の普及によって心房細動患者の脳卒中予防は飛躍的に発展し、多くの患者の命と脳を救ってきました。この領域のオピニオンの1人として、常に最前線の情報収集と発信を行ってきた著者が、あるときふと感じた疑問。「この患者に、本当に抗凝固療法が必要なのだろうか？」抗凝固療法の適用が難しい、超高齢者と脳梗塞低リスクの心房細動患者をどう診るか。その考え方のヒントが、見つかるかもしれません。

目次

  • どうする？　超高齢患者・低リスク患者の抗凝固療法

    ―目次―

    抗凝固療法への新しい提言。「入口戦略」・「出口戦略」とは何か？
    「入口戦略」―低リスク患者への考え方
    私の「入口戦略」
    「出口戦略」―超高齢者への考え方
    出口戦略の糸口「フレイル」
    私の「出口戦略」
    抗凝固療法の知恵(1)　eGFR・クレアチニンクリアランス
    抗凝固療法の知恵(2)　リスクとしての尿酸
    抗凝固療法の知恵(3)　直接経口凝固薬のアドヒアランス

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

文献

P.158 掲載の参考文献
1) Lip GY, et al. Atrial fibrillation patients categorized as "not for anticoagulation" according to the 2014 Canadian Cardiovascular Society algorithm are not "low risk". Can J Cardiol. 2015 Jan ; 31 (1) : 24-8.
 
2) Senoo K, et al. Stroke risk reduction with oral anticoagulation using CHA2DS2-VASc in a Japanese AF population : A modeling analysis. Int J Cardiol. 2015 Feb 15 ; 181 : 247-54.
 
3) Gage BF, et al. Validation of clinical classification schemes for predicting stroke : results from the National Registry of Atrial Fibrillation. JAMA. 2001 Jun 13 ; 285 (22) : 2864-70.
 
4) Lip GY, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach : the euro heart survey on atrial fibrillation. Chest. 2010 Feb ; 137 (2) : 263-72.
PubMed
5) Pisters R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation : the Euro Heart Survey. Chest. 2010 Nov ; 138 (5) : 1093-100.
PubMed
6) Suzuki S, et al. Incidence of ischemic stroke in Japanese patients with atrial fibrillation not receiving anticoagulation therapy-pooled analysis of the Shinken Database, J-RHYTHM Registry, and Fushimi AF Registry. Circ J. 2015 ; 79 (2) : 432-8.
 
7) Oldgren J, et al. ; RE-LY Investigators. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score : a subgroup analysis of the RE-LY trial. Ann Intern Med. 2011 Nov 15 ; 155 (10) : 660-7.
 
8) Lopes RD, et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation : a secondary analysis of a randomised controlled trial. Lancet. 2012 Nov 17 ; 380 (9855) : 1749-58.
 
9) Tanaka K, et al. Pre-admission CHADS2, CHA2DS2-VASc, and R2CHADS2 Scores on Severity and Functional Outcome in Acute Ischemic Stroke with Atrial Fibrillation. J Stroke Cerebrovasc Dis. 2015 Jul ; 24 (7) : 1629-35.
PubMed
10) van den Ham HA, et al. Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation : Results From a National Primary Care Database. J Am Coll Cardiol. 2015 Oct 27 ; 66 (17) : 1851-9.
 
11) Guttmann OP, et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy : systematic review. Heart. 2014 Mar ; 100 (6) : 465-72.
PubMed
12) Kleemann T, et al. Prevalence and clinical impact of left atrial thrombus and dense spontaneous echo contrast in patients with atrial fibrillation and low CHADS2 score. Eur J Echocardiogr. 2009 May ; 10 (3) : 383-8.
PubMed
13) Nozawa T, et al. D-dimer level influences thromboembolic events in patients with atrial fibrillation. Int J Cardiol. 2006 Apr 28 ; 109 (1) : 59-65.
 
14) Tita-Nwa F, et al. Correlates of D-dimer in older persons. Aging Clin Exp Res. 2010 Feb ; 22 (1) : 20-3.
PubMed
15) 平方秀樹,ほか ; 社団法人 日本透析医学会. 血液透析患者における心血管合併症の評価と治療に関するガイドライン. 透析会誌. 2011 ; 44 : 337-425.
 
16) Dharmarajan TS, et al. To anticoagulate or not to anticoagulate? A common dilemma for the provider : physicians' opinion poll based on a case study of an older long-term care facility resident with dementia and atrial fibrillation. J Am Med Dir Assoc. 2006 Jan ; 7 (1) : 23-8.
 
17) 葛谷雅文. フレイルティとは. 臨床栄養. 2011 ; 119 (7) : 755-60.
Medical*Online
18) Fried LP, et al. ; Cardiovascular Health Study Collaborative Research Group. Frailty in older adults : evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001 Mar ; 56 (3) : M146-56.
 
19) Chen MA. Frailty and cardiovascular disease : potential role of gait speed in surgical risk stratification in older adults.J Geriatr Cardiol. 2015 Jan ; 12 (1) : 44-56.
PubMed
20) Wilhelm-Leen ER, et al. Frailty and chronic kidney disease : the Third National Health and Nutrition Evaluation Survey. Am J Med. 2009 Jul ; 122 (7) : 664-71
 
21) Odden MC, et al. Rethinking the association of high blood pressure with mortality in elderly adults : the impact of frailty. Arch Intern Med. 2012 Aug 13 ; 172 (15) : 1162-8.
 
22) Perera V, et al. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing. 2009 Mar ; 38 (2) : 156-62.
PubMed
23) Xue QL, et al. Initial manifestations of frailty criteria and the development of frailty phenotype in the Women's Health and Aging Study II. J Gerontol A Biol Sci Med Sci. 2008 Sep ; 63 (9) : 984-90.
 
24) Mielke MM, et al. Assessing the temporal relationship between cognition and gait : slow gait predicts cognitive decline in the Mayo Clinic Study of Aging. J Gerontol A Biol Sci Med Sci. 2013 Aug ; 68 (8) : 929-37.
 
25) Hughes TF, et al. Association between late-life body mass index and dementia : The Kame Project. Neurology. 2009 May 19 ; 72 (20) : 1741-6.
 
26) Reese PP, et al. ; CRIC Study Investigators. Physical performance and frailty in chronic kidney disease. Am J Nephrol. 2013 ; 38 (4) : 307-15.
 
27) Boffin N, et al. Falls among older general practice patients : a 2-year nationwide surveillance study. Fam Pract. 2014 Jun ; 31 (3) : 281-9.
PubMed
28) Lefebvre MC, et al. The Effect of Bleeding Risk and Frailty Status on Anticoagulation Patterns in Octogenarians With Atrial Fibrillation : The FRAILAF Study. Can J Cardiol. 2016 Feb ; 32 (2) : 169-76.
PubMed
29) Rockwood K, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005 Aug 30 ; 173 (5) : 489-95.
PubMed
30) 公益財団法人 生命保険文化センター.「介護保障ガイド これからの介護リスクに備えるために」 (2015年7月改訂). p. 12.
 
31) 今井圓裕. 日本人に適合したGFR推算法. 日本臨牀 2008 ; 66 (9) : 1725-29.
Medical*Online
32) Letsas KP, et al. Uric acid elevation in atrial fibrillation. Hellenic J Cardiol. 2010 May-Jun ; 51 (3) : 209-13.
 
33) Tamariz L, et al. Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol. 2011 Nov 1 ; 108 (9) : 1272-6.
PubMed
34) Nyrnes A, et al. Uric acid is associated with future atrial fibrillation : an 11-year follow-up of 6308 men and women--the Tromso Study. Europace. 2014 Mar ; 16 (3) : 320-6.
PubMed
35) Suzuki S, et al. Gender-specific relationship between serum uric acid level and atrial fibrillation prevalence. Circ J. 2012 ; 76 (3) : 607-11.
PubMed
36) Chao TF, et al. Hyperuricemia and the risk of ischemic stroke in patients with atrial fibrillation--could it refine clinical risk stratification in AF? Int J Cardiol. 2014 Jan 1 ; 170 (3) : 344-9.
PubMed
37) Tang RB, et al. Serum uric acid and risk of left atrial thrombus in patients with nonvalvular atrial fibrillation. Can J Cardiol. 2014 Nov ; 30 (11) : 1415-21.
PubMed
38) Numa S, et al. Hyperuricemia and transesophageal echocardiographic thromboembolic risk in patients with atrial fibrillation at clinically lowintermediate risk. Circ J. 2014 ; 78 (7) : 1600-5.
PubMed
39) Maharani N, et al. Molecular Mechanisms Underlying Urate-Induced Enhancement of Kv1.5 Channel Expression in HL-1 Atrial Myocytes. Circ J. 2015 Nov 25 ; 79 (12) : 2659-68.
 
40) Shore S, et al. Adherence to dabigatran therapy and longitudinal patient outcomes : insights from the veterans health administration. Am Heart J. 2014 Jun ; 167 (6) : 810-7.
PubMed
41) Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants : considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace. 2015 Apr ; 17 (4) : 514-23.
PubMed
42) Prandoni P. Adherence to the novel oral anticoagulants : an unmet need. Current Medical Research and Opinion. 2015 ; 3 (12) : 2175-7.
 
43) Beyer-Westendorf J, et al. Drug persistence with rivaroxaban therapy in atrial fibrillation patients-results from the Dresden non-interventional oral anticoagulation registry. Europace. 2015 Apr ; 17 (4) : 530-8.
PubMed
44) 心房細動治療 (抗凝固薬) における認知・アドヒアランスの実態調査結果報告書 (平成27年5月29日).株式会社Qlife. http://www.qlife.co.jp/news/150529qlife_research.pdf
 
45) Shore S, et al. Site-level variation in and practices associated with dabigatran adherence. JAMA. 2015 Apr 14 ; 313 (14) : 1443-50.
PubMed

書評

最近チェックした商品履歴

Loading...